healthŌme
healthŌme (now Kadance, Inc.) designs genomics-based precision health programs — heritable cancer risk screening, pharmacogenomic testing, and end-to-end cancer management — embedded as riders in critical illness and life insurance policies distributed through carrier partners such as Chubb.
- Company typePrivate
- Founded2021
- HeadquartersHuntsville, United States
- Headcount11–50
- GTM typeB2B
- OfferingServices
What healthŌme does
healthŌme, Inc. (rebranded Kadance, Inc. effective January 8, 2025) is a genomics-based precision health management company that designs and delivers omics-based products embedded as riders in critical illness and life insurance policies. Founded in 2021 and headquartered at the HudsonAlpha Institute for Biotechnology in Huntsville, Alabama, the company operates a B2B2C model in which life and critical illness insurance carriers license its programs and distribute them to policyholders; Chubb Workplace Benefits holds the exclusive worksite distribution partnership for the flagship Cancer Advocate Plus product, and Hannover Re US serves as reinsurer.
The product portfolio centers on the cancerōme® end-to-end cancer management program, which combines heritable cancer risk screening (healthŌme One™ test of 30 cancer-risk genes), pharmacogenomic drug-response testing, expert medical review, 1:1 oncology nurse navigation, clinical trial identification, and DNA-based recurrence monitoring. In March 2024, the company expanded into medication safety via a partnership with GalenusRx integrating the APPRAISE™ drug-drug, drug-gene, and drug-disease interaction platform. The May 2023 acquisition of Kailos Genetics, a CLIA-certified and CAP-accredited genetic testing laboratory and NGS reagent supplier, provides vertically integrated lab capabilities; Kailos also serves third-party clients. Supporting clinical services are delivered through partners including SteadyMD (telemedicine/genetic counseling), Protean Biodiagnostics, and Access Genetics.
The company monetizes through licensing fees and per-policyholder program fees paid by insurance carriers (subscription/recurring model), supplemented by third-party lab services revenue from Kailos. The preferred seed funding round closed in May 2024 (~$8.44M) was co-led by American Family Ventures and AllegisNL Capital, with Hannover Re as a strategic reinsurance partner; the company won the 2024 Global Innovation Award from the International Insurance Society, Insurance Thought Leadership, and Lloyd's. The leadership team comprises a CEO with healthcare and genomics commercialization background, a CCO with genomics-industry tenure (ex-Illumina, Applied Biosystems, St. Jude), a COO ex-Hannover Re, the former CTO of Kailos Genetics as CTO, and a former Illinois/Connecticut Commissioner of Insurance as Board Chair.
healthŌme firmographics
Firmographics- Name
- healthŌme
- Legal name
- healthOme, Inc.
- Website
- https://healthome.com
- Company type
- Private
- Founded year
- 2021
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- healthŌme (now Kadance, Inc.) designs genomics-based precision health programs — heritable cancer risk screening, pharmacogenomic testing, and end-to-end cancer management — embedded as riders in critical illness and life insurance policies distributed through carrier partners such as Chubb.
- Ownership category
- akta.pro rank
healthŌme industry classification
Industry- Product category
- Genomics-Based Precision Health Management for Insurance
- NAICS
- Direct Health and Medical Insurance Carriers (524114), Direct Life Insurance Carriers (524113), Insurance Agencies and Brokerages (524210)
- SIC
- Accident & Health Insurance (6321), Insurance Agents, Brokers & Service (6411), Services-Health Services (8000)
- akta.pro primary industry
- Worksite Cancer / Specified Disease Insurance (FSAIAMAI)
- akta.pro secondary industry
- Multi-Omics Precision Medicine Platforms (genomics/proteomics/metabolomics) (HLAAANAF)
Keywords
Where healthŌme is headquartered
LocationHeadquarters
- HQ city
- Huntsville
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
healthŌme business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure, Supply Chain
Revenue model
- B2B2C Insurance Carrier Licensing & Program Fees: healthŌme designs and delivers tech-enabled precision health management programs through a network of life and critical illness insurance carriers. Carriers embed healthŌme products as riders to existing policies or as standalone disease-specific policies. Revenue is derived from licensing fees or per-policyholder program fees paid by insurance carriers. The company provides heritable cancer risk screening, pharmacogenomic testing, precision cancer management, and nurse navigation services to policyholders on behalf of carriers.
- Kailos Genetics Laboratory Services: Kailos Genetics, a wholly-owned subsidiary of healthŌme, provides genetic testing laboratory services and clinical grade laboratory reagents for next-generation sequencing to the marketplace, including third-party clients beyond healthŌme's insurance partnerships.
- GalenusRx Partnership - Medication Safety Program: Through the partnership with GalenusRx, policyholder access to pharmacogenomic testing and precision clinical pharmacist consultations generates value through reduced adverse drug events and improved medication management outcomes for insurance carriers.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Multi-year contract | Insurance policy rider — no additional cost to eligible policyholders |
Go-to-market motion2 records
Distribution channels3 records
Marketing channels7 records
healthŌme product offering
Product offeringCore offering
healthŌme creates omics-based products for the critical illness and life insurance industry, integrating heritable cancer risk screening, pharmacogenomic testing, precision cancer management (nurse navigation, expert medical review, clinical trial matching), DNA-based recurrence monitoring, and medication safety analysis into insurance policies as riders. Programs are licensed to insurance carriers (including Chubb Workplace Benefits) who deliver them to policyholders as day-one living benefits, supported by the company's in-house CLIA-certified and CAP-accredited Kailos Genetics laboratory.
Product overview
healthŌme is a genomics-based precision health management platform operating at the intersection of life insurance, life science, and health management. The company offers a unified platform with multiple integrated products: the core cancerŌme® program provides end-to-end cancer management combining hereditary cancer risk screening (healthŌme One™ test), pharmacogenomic testing, and precision cancer management with genomic profiling and nurse navigation. Kadance serves as the consumer-facing brand for these services. The product portfolio also includes a Personalized Medication Safety Program powered by GalenusRx's APPRAISE™ platform. The company operates through a fully integrated in-house genetics lab (Kailos Genetics) and distributes through life and critical illness insurance carriers, with products offered as riders to existing insurance policies. Following the January 2025 rebrand, the company operates under Kadance, Inc.
Differentiator
Problem solved
Functional benefit
Brands
- Kadance: Insurance program providing DNA-powered health management with focus on cancer management and pharmacogenomics.
- cancerŌme
Products and services
- cancerōme® Cancer Management Program A first-of-its-kind, patent-pending omics-based insurance program delivering end-to-end cancer management from heritable risk screening through diagnosis, treatment, and recurrence monitoring. Designed for individual policyholders of participating life and critical illness insurance policies and licensed to insurance carriers as a differentiated rider offering.
- healthōme One™ Heritable Cancer Risk Screening Test Clinical-grade at-home genetic screening test analyzing 30 different inherited genes known to increase cancer risk. Includes genetic counseling and a personalized action plan for individuals identified with above-average cancer risk. Offered as a day-one benefit to eligible insurance policyholders.
- Pharmacogenomic (PGx) Drug Response Testing Clinical-grade pharmacogenomic testing that indicates how an individual will respond to particular medications, the likelihood of adverse drug reactions, and optimal medication dosage based on genetic profile. Approximately 95% of the population has a genetic variant affecting medication metabolism. Provided to eligible insurance policyholders.
- DNA-based Cancer Recurrence Monitoring Blood-based genetic test that tracks tiny traces of cancer in the blood to detect returning cancer earlier than traditional medical testing. Used during the cancer survivorship and recovery phase for policyholders who have completed initial treatment.
- Personalized Medication Safety Program Genomics-based medication safety program that integrates a policyholder's pharmacogenomic test results with GalenusRx's APPRAISE™ medication-safety platform. Produces a Personalized Medication Safety Plan via drug-drug, multi-drug, drug-gene, and drug-disease interaction analysis, and includes precision clinical pharmacist telehealth consultations to reduce adverse drug events.
- Kailos Genetics Laboratory Services Clinical-grade genetic testing laboratory services and supply of clinical-grade laboratory reagents for next-generation sequencing, provided by Kailos Genetics (a wholly-owned subsidiary of healthŌme). Serves both healthŌme's insurance policyholder programs and third-party clients in the broader genetic testing market.
Quantifiable outcome
- Five-year survival rate for early-stage cancers is 91.1% compared to 30.6% for late-stage cancers — early detection through genetic screening dramatically improves survivability
- +3 more outcomes
Companies that use healthŌme
Customer profileNamed customers1 record
Segments3 records
Ideal customer profiles3 records
healthŌme technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration5 records
AI capability7 records
Feature5 records
healthŌme partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered core and minor.
- Hannover Re AmericacoreHannover Re is the reinsurer for healthŌme's first-of-its-kind cancer management program. Vice President Julian Whitekus serves as board observer. Hannover Re collaborated with healthŌme on integrating genomics-based services into critical illness and life insurance products, demonstrating how the partnership empowers insurers to improve product offerings and enhance member engagement.
- GalenusRx, Inc.coreStrategic partnership to launch a genomics-based personalized medication safety program. GalenusRx provides its APPRAISE™ proprietary medication safety technology and precision clinical pharmacists who deliver medication safety insights and consultations. The partnership integrates GalenusRx's clinical pharmacy expertise with healthŌme's pharmacogenomic testing and policyholder platform to reduce adverse drug events for policyholders.
- Kailos Genetics, LLCcoreKailos Genetics, a CLIA-certified and CAP-accredited genetic testing laboratory and supplier of clinical grade laboratory reagents for next-generation sequencing, was acquired by healthŌme on May 31, 2023, and became a wholly-owned subsidiary. Kailos continues to provide its full range of genetic testing services and reagents to the marketplace in addition to serving healthŌme. David Kloske, former CTO of Kailos Genetics, became CTO of healthŌme.
- Chubb Workplace BenefitscoreExclusive distribution partnership for Cancer Advocate Plus, a first-of-its-kind genetics-based cancer program distributed through Chubb's voluntary benefits worksite channel to employees of middle-market and large companies. Chubb provides insurance underwriting while healthŌme delivers all genomics services including heritable cancer risk screening, pharmacogenomic testing, and precision cancer management.
- HudsonAlpha Institute for BiotechnologyminorhealthŌme and Kailos Genetics are both resident associate companies at the HudsonAlpha Institute for Biotechnology in Huntsville, Alabama. HudsonAlpha provides laboratory facilities and an ecosystem of biotech innovation. Founder Jim Hudson noted the strategic value of combining two HudsonAlpha associate companies to advance healthcare solutions.
Scale indicators5 records
Recent moves7 records
healthŌme competitors and assessment
Company assessmentMarket position
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
healthŌme social profiles
Digital presencehealthŌme compliance and trust
Trust signalCompliance1 record
healthŌme financial estimates
Financial estimateRevenue estimate
Valuation estimate
healthŌme leadership team
Management profileNumber of profiles
Profiles10 records
healthŌme subsidiaries and ownership
Company hierarchySubsidiaries1 record
healthŌme funding detail
Funding detailFunding overview
Funding rounds1 record
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
healthŌme M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about healthŌme
What does healthŌme do?
healthŌme creates omics-based products for the critical illness and life insurance industry, integrating heritable cancer risk screening, pharmacogenomic testing, precision cancer management (nurse navigation, expert medical review, clinical trial matching), DNA-based recurrence monitoring, and medication safety analysis into insurance policies as riders. Programs are licensed to insurance carriers (including Chubb Workplace Benefits) who deliver them to policyholders as day-one living benefits, supported by the company's in-house CLIA-certified and CAP-accredited Kailos Genetics laboratory.
Is healthŌme a public or private company?
healthŌme is a private company. It is classified as venture growth investor backed and is currently operating.
When was healthŌme founded?
healthŌme was founded in 2021. It employs 11 to 50 people.
Where is healthŌme based?
healthŌme is headquartered in Huntsville, United States, in the North America region.
How does healthŌme make money?
Three revenue lines are on record. B2B2C Insurance Carrier Licensing & Program Fees are the primary driver. The others are kailos Genetics Laboratory Services and galenusRx Partnership - Medication Safety Program.
Does healthŌme have an API?
No public API is recorded for healthŌme.
What industry is healthŌme in?
healthŌme's product category is Genomics-Based Precision Health Management for Insurance. Its primary akta.pro industry code is FSAIAMAI, Worksite Cancer / Specified Disease Insurance, with a secondary code of HLAAANAF, Multi-Omics Precision Medicine Platforms (genomics/proteomics/metabolomics). Its NAICS code is 524114 and its SIC code is 6321.